{"product_id":"s4andarine-1g","title":"S4(Andarine) 1g","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003eFOR HUMAN \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eCONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eS4 \u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e(Andarine, GTx-007) is a \u003cstrong data-end=\"181\" data-start=\"120\"\u003enonsteroidal selective androgen receptor modulator (SARM)\u003c\/strong\u003e developed by GTx for \u003cstrong data-end=\"275\" data-start=\"203\"\u003eosteoporosis, muscle wasting, and benign prostatic hyperplasia (BPH)\u003c\/strong\u003e. It binds the \u003cstrong data-end=\"316\" data-start=\"290\"\u003eandrogen receptor (AR)\u003c\/strong\u003e with tissue-selective, \u003cstrong data-end=\"359\" data-start=\"340\"\u003epartial agonist\u003c\/strong\u003e activity—aiming to \u003cstrong data-end=\"408\" data-start=\"379\"\u003estimulate bone and muscle\u003c\/strong\u003e while \u003cstrong data-end=\"454\" data-start=\"415\"\u003esparing prostate and hair follicles\u003c\/strong\u003e relative to testosterone\/DHT. Clinical development never reached approval; most human data are \u003cstrong data-end=\"565\" data-start=\"550\"\u003eearly-phase\u003c\/strong\u003e. It is \u003cstrong data-end=\"589\" data-start=\"573\"\u003enot approved\u003c\/strong\u003e for any indication and is \u003cstrong data-end=\"638\" data-start=\"616\"\u003eprohibited by WADA\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-end=\"644\" data-start=\"641\"\u003e\n\u003ch3 data-end=\"700\" data-start=\"646\"\u003eAdditional Benefits of S-4 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2630\" data-start=\"702\"\u003e\n\u003cthead data-end=\"730\" data-start=\"702\"\u003e\n\u003ctr data-end=\"730\" data-start=\"702\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"712\" data-start=\"702\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"730\" data-start=\"712\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2630\" data-start=\"741\"\u003e\n\u003ctr data-end=\"1006\" data-start=\"741\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"772\" data-start=\"741\"\u003e\u003cstrong data-end=\"771\" data-start=\"743\"\u003e1 Lean mass preservation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1006\" data-start=\"772\"\u003eIn animal and early human studies, S-4 increases \u003cstrong data-end=\"841\" data-start=\"823\"\u003elean body mass\u003c\/strong\u003e and \u003cstrong data-end=\"865\" data-start=\"846\"\u003emuscle strength\u003c\/strong\u003e or preserves them during \u003cstrong data-end=\"926\" data-start=\"891\"\u003ehypogonadism or caloric deficit\u003c\/strong\u003e, with less virilization than anabolic steroids at comparable anabolic effect.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1239\" data-start=\"1007\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1036\" data-start=\"1007\"\u003e\u003cstrong data-end=\"1035\" data-start=\"1009\"\u003e2 Bone-density support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1239\" data-start=\"1036\"\u003eS-4 improves \u003cstrong data-end=\"1081\" data-start=\"1051\"\u003ebone mineral density (BMD)\u003c\/strong\u003e and \u003cstrong data-end=\"1112\" data-start=\"1086\"\u003ebiomechanical strength\u003c\/strong\u003e in osteopenic\/ovariectomized models, mimicking some of testosterone’s skeletal benefits without strong prostate stimulation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1480\" data-start=\"1240\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1281\" data-start=\"1240\"\u003e\u003cstrong data-end=\"1280\" data-start=\"1242\"\u003e3 Prostate-sparing androgen action\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1480\" data-start=\"1281\"\u003eIn castrated rodent models, S-4 \u003cstrong data-end=\"1339\" data-start=\"1315\"\u003esupports muscle\/bone\u003c\/strong\u003e while causing \u003cstrong data-end=\"1383\" data-start=\"1354\"\u003eless prostate enlargement\u003c\/strong\u003ethan DHT and even \u003cstrong data-end=\"1429\" data-start=\"1402\"\u003ereduces prostate weight\u003c\/strong\u003e under some conditions—basis for its BPH program.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1674\" data-start=\"1481\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1512\" data-start=\"1481\"\u003e\u003cstrong data-end=\"1511\" data-start=\"1483\"\u003e4 Functional performance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1674\" data-start=\"1512\"\u003ePreclinical work shows \u003cstrong data-end=\"1611\" data-start=\"1537\"\u003eincreased grip strength, running time, and muscle cross-sectional area\u003c\/strong\u003e, indicating true functional gains, not just water retention.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1876\" data-start=\"1675\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1715\" data-start=\"1675\"\u003e\u003cstrong data-end=\"1714\" data-start=\"1677\"\u003e5 Potential cachexia applications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1876\" data-start=\"1715\"\u003eThe combination of \u003cstrong data-end=\"1767\" data-start=\"1736\"\u003eanabolic and anti-catabolic\u003c\/strong\u003e actions suggests utility for \u003cstrong data-end=\"1832\" data-start=\"1797\"\u003ecancer\/illness-related cachexia\u003c\/strong\u003e; this remains theoretical and unapproved.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2006\" data-start=\"1877\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1899\" data-start=\"1877\"\u003e\u003cstrong data-end=\"1898\" data-start=\"1879\"\u003e6 Oral delivery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2006\" data-start=\"1899\"\u003eS-4 is \u003cstrong data-end=\"1931\" data-start=\"1908\"\u003eorally bioavailable\u003c\/strong\u003e, avoiding injections and allowing once- or twice-daily dosing in trials.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2220\" data-start=\"2007\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2037\" data-start=\"2007\"\u003e\u003cstrong data-end=\"2036\" data-start=\"2009\"\u003e7 Lower androgenic load\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2220\" data-start=\"2037\"\u003eCompared to full AR agonists, S-4’s \u003cstrong data-end=\"2094\" data-start=\"2075\"\u003epartial agonism\u003c\/strong\u003e and tissue selectivity lead to \u003cstrong data-end=\"2179\" data-start=\"2126\"\u003eless virilization, acne, and prostate stimulation\u003c\/strong\u003e at anabolic doses in preclinical work.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2413\" data-start=\"2221\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2251\" data-start=\"2221\"\u003e\u003cstrong data-end=\"2250\" data-start=\"2223\"\u003e8 Limited aromatization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2413\" data-start=\"2251\"\u003eBeing nonsteroidal, it does \u003cstrong data-end=\"2311\" data-start=\"2281\"\u003enot aromatize to estradiol\u003c\/strong\u003e or reduce 5-α reductase; E2 shifts are secondary (via HPT-axis suppression), not direct conversion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2630\" data-start=\"2414\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2459\" data-start=\"2414\"\u003e\u003cstrong data-end=\"2458\" data-start=\"2416\"\u003e9 Conceptual stacking with other SARMs\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2630\" data-start=\"2459\"\u003eIn research, S-4 has been explored as a \u003cstrong data-end=\"2525\" data-start=\"2501\"\u003ebone-\/cutting-biased\u003c\/strong\u003e SARM alongside more potent anabolic SARMs; this is entirely experimental and not clinically validated.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2635\" data-start=\"2632\"\u003e\n\u003ch2 data-end=\"2672\" data-start=\"2637\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"2709\" data-start=\"2674\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"3246\" data-start=\"2711\"\u003e\n\u003cli data-end=\"2876\" data-start=\"2711\"\u003e\n\u003cp data-end=\"2876\" data-start=\"2713\"\u003e\u003cstrong data-end=\"2724\" data-start=\"2713\"\u003eTarget:\u003c\/strong\u003e Andarine binds the \u003cstrong data-end=\"2770\" data-start=\"2744\"\u003eandrogen receptor (AR)\u003c\/strong\u003e as a \u003cstrong data-end=\"2795\" data-start=\"2776\"\u003epartial agonist\u003c\/strong\u003e with a distinct co-activator recruitment profile compared to DHT\/testosterone.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3246\" data-start=\"2877\"\u003e\n\u003cp data-end=\"2904\" data-start=\"2879\"\u003e\u003cstrong data-end=\"2902\" data-start=\"2879\"\u003eTissue selectivity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"3246\" data-start=\"2907\"\u003e\n\u003cli data-end=\"3063\" data-start=\"2907\"\u003e\n\u003cp data-end=\"3063\" data-start=\"2909\"\u003e\u003cstrong data-end=\"2936\" data-start=\"2909\"\u003eSkeletal muscle \u0026amp; bone:\u003c\/strong\u003e Acts more like an \u003cstrong data-end=\"2966\" data-start=\"2955\"\u003eagonist\u003c\/strong\u003e, promoting \u003cstrong data-end=\"2999\" data-start=\"2978\"\u003eprotein synthesis\u003c\/strong\u003e, \u003cstrong data-end=\"3019\" data-start=\"3001\"\u003eantiresorptive\u003c\/strong\u003e signaling, and \u003cstrong data-end=\"3060\" data-start=\"3035\"\u003eosteoblastic activity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3246\" data-start=\"3066\"\u003e\n\u003cp data-end=\"3246\" data-start=\"3068\"\u003e\u003cstrong data-end=\"3104\" data-start=\"3068\"\u003eProstate \u0026amp; reproductive tissues:\u003c\/strong\u003e Behaves \u003cstrong data-end=\"3130\" data-start=\"3113\"\u003eless strongly\u003c\/strong\u003e than DHT; in some models, functions almost as a \u003cstrong data-end=\"3204\" data-start=\"3179\"\u003efunctional antagonist\u003c\/strong\u003e by competing with endogenous androgens.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3275\" data-start=\"3248\"\u003e2.2 Down-stream biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3703\" data-start=\"3277\"\u003e\n\u003cthead data-end=\"3319\" data-start=\"3277\"\u003e\n\u003ctr data-end=\"3319\" data-start=\"3277\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3287\" data-start=\"3277\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3308\" data-start=\"3287\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3319\" data-start=\"3308\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3703\" data-start=\"3334\"\u003e\n\u003ctr data-end=\"3430\" data-start=\"3334\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3361\" data-start=\"3334\"\u003e\u003cstrong data-end=\"3360\" data-start=\"3336\"\u003eAR–ARE transcription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3411\" data-start=\"3361\"\u003e↑ Myofibrillar protein synthesis, ↓ proteolysis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3430\" data-start=\"3411\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3510\" data-start=\"3431\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3477\" data-start=\"3431\"\u003e\u003cstrong data-end=\"3476\" data-start=\"3433\"\u003eRANKL\/OPG balance \u0026amp; osteoblast activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3502\" data-start=\"3477\"\u003e↑ BMD, ↑ bone strength\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3510\" data-start=\"3502\"\u003eBone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3611\" data-start=\"3511\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3545\" data-start=\"3511\"\u003e\u003cstrong data-end=\"3544\" data-start=\"3513\"\u003eProstate AR partial agonism\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3597\" data-start=\"3545\"\u003e↓ Prostate weight vs DHT at equal anabolic effect\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3611\" data-start=\"3597\"\u003eBPH models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3703\" data-start=\"3612\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3636\" data-start=\"3612\"\u003e\u003cstrong data-end=\"3635\" data-start=\"3614\"\u003eHPT-axis feedback\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3681\" data-start=\"3636\"\u003e↓ LH\/FSH → ↓ endogenous T with chronic use\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3703\" data-start=\"3681\"\u003eSystemic endocrine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3708\" data-start=\"3705\"\u003e\n\u003ch2 data-end=\"3772\" data-start=\"3710\"\u003e3. Pharmacokinetics (from early studies \u0026amp; preclinical data)\u003c\/h2\u003e\n\u003cul data-end=\"4280\" data-start=\"3774\"\u003e\n\u003cli data-end=\"3839\" data-start=\"3774\"\u003e\n\u003cp data-end=\"3839\" data-start=\"3776\"\u003e\u003cstrong data-end=\"3786\" data-start=\"3776\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-end=\"3795\" data-start=\"3787\"\u003eOral\u003c\/strong\u003e, typically once or twice daily in trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3954\" data-start=\"3840\"\u003e\n\u003cp data-end=\"3954\" data-start=\"3842\"\u003e\u003cstrong data-end=\"3856\" data-start=\"3842\"\u003eHalf-life:\u003c\/strong\u003e On the order of \u003cstrong data-end=\"3899\" data-start=\"3873\"\u003ehours (short–moderate)\u003c\/strong\u003e; supports BID dosing in many experimental protocols.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4013\" data-start=\"3955\"\u003e\n\u003cp data-end=\"4013\" data-start=\"3957\"\u003e\u003cstrong data-end=\"3972\" data-start=\"3957\"\u003eAbsorption:\u003c\/strong\u003e Good oral bioavailability; lipophilic.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4124\" data-start=\"4014\"\u003e\n\u003cp data-end=\"4124\" data-start=\"4016\"\u003e\u003cstrong data-end=\"4033\" data-start=\"4016\"\u003eDistribution:\u003c\/strong\u003e Binds AR in muscle, bone, prostate, and other AR-rich tissues; crosses into many organs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4219\" data-start=\"4125\"\u003e\n\u003cp data-end=\"4219\" data-start=\"4127\"\u003e\u003cstrong data-end=\"4142\" data-start=\"4127\"\u003eMetabolism:\u003c\/strong\u003e Hepatic metabolic clearance; exact CYP profile not publicly characterized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4280\" data-start=\"4220\"\u003e\n\u003cp data-end=\"4280\" data-start=\"4222\"\u003e\u003cstrong data-end=\"4236\" data-start=\"4222\"\u003eExcretion:\u003c\/strong\u003e Primarily renal and biliary as metabolites.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4285\" data-start=\"4282\"\u003e\n\u003ch2 data-end=\"4325\" data-start=\"4287\"\u003e4. Pre-clinical \u0026amp; Clinical Evidence\u003c\/h2\u003e\n\u003cul data-end=\"4920\" data-start=\"4327\"\u003e\n\u003cli data-end=\"4488\" data-start=\"4327\"\u003e\n\u003cp data-end=\"4488\" data-start=\"4329\"\u003e\u003cstrong data-end=\"4358\" data-start=\"4329\"\u003eOsteoporosis\/Bone models:\u003c\/strong\u003e S-4 restored \u003cstrong data-end=\"4397\" data-start=\"4372\"\u003eBMD and bone strength\u003c\/strong\u003e in ovariectomized rats while keeping \u003cstrong data-end=\"4467\" data-start=\"4435\"\u003eprostate size relatively low\u003c\/strong\u003e compared with DHT.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4683\" data-start=\"4489\"\u003e\n\u003cp data-end=\"4683\" data-start=\"4491\"\u003e\u003cstrong data-end=\"4530\" data-start=\"4491\"\u003eMuscle wasting\/hypogonadism models:\u003c\/strong\u003e Improved \u003cstrong data-end=\"4566\" data-start=\"4540\"\u003elean mass and strength\u003c\/strong\u003e, outperforming placebo and approaching low-dose testosterone’s anabolic effect with less androgenic tissue impact.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4920\" data-start=\"4684\"\u003e\n\u003cp data-end=\"4920\" data-start=\"4686\"\u003e\u003cstrong data-end=\"4724\" data-start=\"4686\"\u003eBPH\/androgen-deprivation settings:\u003c\/strong\u003e Showed ability to \u003cstrong data-end=\"4767\" data-start=\"4743\"\u003emaintain muscle\/bone\u003c\/strong\u003e under androgen deprivation while \u003cstrong data-end=\"4841\" data-start=\"4801\"\u003enot excessively stimulating prostate\u003c\/strong\u003e, making it attractive in theory as an adjunct to androgen-deprivation therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-end=\"5176\" data-start=\"4922\"\u003e\n\u003cp data-end=\"5176\" data-start=\"4924\"\u003e\u003cstrong data-end=\"4950\" data-start=\"4924\"\u003eEvidence quality note:\u003c\/strong\u003e Most data are \u003cstrong data-end=\"4983\" data-start=\"4965\"\u003eanimal studies\u003c\/strong\u003e plus \u003cstrong data-end=\"5024\" data-start=\"4989\"\u003esmall, early-phase human trials\u003c\/strong\u003e. There are \u003cstrong data-end=\"5061\" data-start=\"5036\"\u003eno large Phase 3 data\u003c\/strong\u003e, no approved indications, and the full risk–benefit profile at therapeutic doses remains \u003cstrong data-end=\"5175\" data-start=\"5151\"\u003eincompletely defined\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"5181\" data-start=\"5178\"\u003e\n\u003ch2 data-end=\"5229\" data-start=\"5183\"\u003e5. Emerging Clinical Interests (conceptual)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5771\" data-start=\"5231\"\u003e\n\u003cthead data-end=\"5261\" data-start=\"5231\"\u003e\n\u003ctr data-end=\"5261\" data-start=\"5231\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"5239\" data-start=\"5231\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5251\" data-start=\"5239\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5261\" data-start=\"5251\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5771\" data-start=\"5276\"\u003e\n\u003ctr data-end=\"5378\" data-start=\"5276\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5313\" data-start=\"5276\"\u003e\u003cstrong data-end=\"5312\" data-start=\"5278\"\u003eMale osteoporosis \/ osteopenia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5348\" data-start=\"5313\"\u003eBone-anabolic + prostate-sparing\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5378\" data-start=\"5348\"\u003ePreclinical\/early clinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5465\" data-start=\"5379\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5406\" data-start=\"5379\"\u003e\u003cstrong data-end=\"5405\" data-start=\"5381\"\u003eSarcopenia \/ frailty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5454\" data-start=\"5406\"\u003eMuscle maintenance with lower androgenic load\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5465\" data-start=\"5454\"\u003eConcept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5553\" data-start=\"5466\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5498\" data-start=\"5466\"\u003e\u003cstrong data-end=\"5497\" data-start=\"5468\"\u003eCachexia (cancer\/HIV\/CHF)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5530\" data-start=\"5498\"\u003eAnticatabolic, oral, anabolic\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5553\" data-start=\"5530\"\u003ePreclinical concept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5670\" data-start=\"5554\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5606\" data-start=\"5554\"\u003e\u003cstrong data-end=\"5605\" data-start=\"5556\"\u003eAdjunct in androgen-deprivation (prostate CA)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5643\" data-start=\"5606\"\u003ePreserve muscle\/bone, not prostate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5670\" data-start=\"5643\"\u003eConcept; safety complex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5771\" data-start=\"5671\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5715\" data-start=\"5671\"\u003e\u003cstrong data-end=\"5714\" data-start=\"5673\"\u003eFemale osteoporosis (post-menopausal)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5751\" data-start=\"5715\"\u003eBone support without virilization\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5771\" data-start=\"5751\"\u003eAnimal data only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5776\" data-start=\"5773\"\u003e\n\u003ch2 data-end=\"5807\" data-start=\"5778\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cp data-end=\"5960\" data-start=\"5809\"\u003e\u003cstrong data-end=\"5823\" data-start=\"5809\"\u003eImportant:\u003c\/strong\u003e Much of the human safety profile is inferred from \u003cstrong data-end=\"5896\" data-start=\"5874\"\u003elimited trial data\u003c\/strong\u003e and \u003cstrong data-end=\"5930\" data-start=\"5901\"\u003eoff-label\/grey-market use\u003c\/strong\u003e, not long, high-quality RCTs.\u003c\/p\u003e\n\u003ch3 data-end=\"5998\" data-start=\"5962\"\u003e6.1 Commonly reported \/ expected\u003c\/h3\u003e\n\u003cul data-end=\"6957\" data-start=\"6000\"\u003e\n\u003cli data-end=\"6350\" data-start=\"6000\"\u003e\n\u003cp data-end=\"6046\" data-start=\"6002\"\u003e\u003cstrong data-end=\"6044\" data-start=\"6002\"\u003eVisual disturbances (hallmark of S-4):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"6350\" data-start=\"6049\"\u003e\n\u003cli data-end=\"6107\" data-start=\"6049\"\u003e\n\u003cp data-end=\"6107\" data-start=\"6051\"\u003e\u003cstrong data-end=\"6066\" data-start=\"6051\"\u003eYellow tint\u003c\/strong\u003e to vision or altered color perception.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6176\" data-start=\"6110\"\u003e\n\u003cp data-end=\"6176\" data-start=\"6112\"\u003e\u003cstrong data-end=\"6139\" data-start=\"6112\"\u003eNight-vision difficulty\u003c\/strong\u003e (reduced adaptation in low light).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6350\" data-start=\"6179\"\u003e\n\u003cp data-end=\"6350\" data-start=\"6181\"\u003eUsually dose-related and reversible after discontinuation in reports; likely due to S-4 or its metabolites affecting \u003cstrong data-end=\"6319\" data-start=\"6298\"\u003eretinal signaling\u003c\/strong\u003e (exact mechanism uncertain).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6554\" data-start=\"6351\"\u003e\n\u003cp data-end=\"6381\" data-start=\"6353\"\u003e\u003cstrong data-end=\"6379\" data-start=\"6353\"\u003eEndocrine suppression:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"6554\" data-start=\"6384\"\u003e\n\u003cli data-end=\"6466\" data-start=\"6384\"\u003e\n\u003cp data-end=\"6466\" data-start=\"6386\"\u003eDecreased \u003cstrong data-end=\"6406\" data-start=\"6396\"\u003eLH\/FSH\u003c\/strong\u003e, \u003cstrong data-end=\"6439\" data-start=\"6408\"\u003etotal and free testosterone\u003c\/strong\u003e with prolonged exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6554\" data-start=\"6469\"\u003e\n\u003cp data-end=\"6554\" data-start=\"6471\"\u003ePotential \u003cstrong data-end=\"6503\" data-start=\"6481\"\u003etesticular atrophy\u003c\/strong\u003e and transient \u003cstrong data-end=\"6534\" data-start=\"6518\"\u003esubfertility\u003c\/strong\u003e with chronic use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6732\" data-start=\"6555\"\u003e\n\u003cp data-end=\"6732\" data-start=\"6557\"\u003e\u003cstrong data-end=\"6577\" data-start=\"6557\"\u003eAndrogenic\/skin:\u003c\/strong\u003e Mild \u003cstrong data-end=\"6591\" data-start=\"6583\"\u003eacne\u003c\/strong\u003e, \u003cstrong data-end=\"6606\" data-start=\"6593\"\u003eoily skin\u003c\/strong\u003e, \u003cstrong data-end=\"6625\" data-start=\"6608\"\u003ehair shedding\u003c\/strong\u003e in susceptible individuals—generally milder than full androgenic steroids at equivalent anabolic effect.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6827\" data-start=\"6733\"\u003e\n\u003cp data-end=\"6827\" data-start=\"6735\"\u003e\u003cstrong data-end=\"6746\" data-start=\"6735\"\u003eLipids:\u003c\/strong\u003e \u003cstrong data-end=\"6764\" data-start=\"6747\"\u003eHDL reduction\u003c\/strong\u003e and possible \u003cstrong data-end=\"6794\" data-start=\"6778\"\u003eLDL increase\u003c\/strong\u003e, as with many androgens\/SARMs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6957\" data-start=\"6828\"\u003e\n\u003cp data-end=\"6957\" data-start=\"6830\"\u003e\u003cstrong data-end=\"6840\" data-start=\"6830\"\u003eLiver:\u003c\/strong\u003e Mild \u003cstrong data-end=\"6868\" data-start=\"6846\"\u003eALT\/AST elevations\u003c\/strong\u003e reported anecdotally; robust hepatotoxicity data are lacking but caution is appropriate.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"6992\" data-start=\"6959\"\u003e6.2 Less common \/ theoretical\u003c\/h3\u003e\n\u003cul data-end=\"7570\" data-start=\"6994\"\u003e\n\u003cli data-end=\"7114\" data-start=\"6994\"\u003e\n\u003cp data-end=\"7114\" data-start=\"6996\"\u003e\u003cstrong data-end=\"7016\" data-start=\"6996\"\u003eCardiometabolic:\u003c\/strong\u003e Possible \u003cstrong data-end=\"7042\" data-start=\"7026\"\u003eBP increases\u003c\/strong\u003e, \u003cstrong data-end=\"7064\" data-start=\"7044\"\u003ehematocrit drift\u003c\/strong\u003e, and unknown long-term \u003cstrong data-end=\"7111\" data-start=\"7088\"\u003ecardiovascular risk\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7241\" data-start=\"7115\"\u003e\n\u003cp data-end=\"7241\" data-start=\"7117\"\u003e\u003cstrong data-end=\"7137\" data-start=\"7117\"\u003eMood\/neurologic:\u003c\/strong\u003e Some users report \u003cstrong data-end=\"7190\" data-start=\"7156\"\u003eirritability, decreased libido\u003c\/strong\u003e with endogenous suppression; data are anecdotal.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7394\" data-start=\"7242\"\u003e\n\u003cp data-end=\"7394\" data-start=\"7244\"\u003e\u003cstrong data-end=\"7261\" data-start=\"7244\"\u003eReproductive:\u003c\/strong\u003e Potential impact on \u003cstrong data-end=\"7301\" data-start=\"7282\"\u003espermatogenesis\u003c\/strong\u003e and fertility with long-term use; recovery time after cessation is not well characterized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7570\" data-start=\"7395\"\u003e\n\u003cp data-end=\"7570\" data-start=\"7397\"\u003e\u003cstrong data-end=\"7410\" data-start=\"7397\"\u003eOncology:\u003c\/strong\u003e Long-term \u003cstrong data-end=\"7435\" data-start=\"7421\"\u003etumor risk\u003c\/strong\u003e with chronic partial AR stimulation\/inhibition has not been mapped; caution in anyone with a history of \u003cstrong data-end=\"7569\" data-start=\"7540\"\u003ehormone-sensitive cancers\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"7606\" data-start=\"7572\"\u003e6.3 Anti-doping \/ legal status\u003c\/h3\u003e\n\u003cul data-end=\"7933\" data-start=\"7608\"\u003e\n\u003cli data-end=\"7712\" data-start=\"7608\"\u003e\n\u003cp data-end=\"7712\" data-start=\"7610\"\u003e\u003cstrong data-end=\"7619\" data-start=\"7610\"\u003eWADA:\u003c\/strong\u003e SARMs (including \u003cstrong data-end=\"7653\" data-start=\"7637\"\u003eS-4\/Andarine\u003c\/strong\u003e) are \u003cstrong data-end=\"7686\" data-start=\"7659\"\u003eprohibited at all times\u003c\/strong\u003e (S1.2 anabolic agents).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7933\" data-start=\"7713\"\u003e\n\u003cp data-end=\"7933\" data-start=\"7715\"\u003e\u003cstrong data-end=\"7730\" data-start=\"7715\"\u003eRegulation:\u003c\/strong\u003e S-4 is \u003cstrong data-end=\"7768\" data-start=\"7738\"\u003enot an approved medication\u003c\/strong\u003e; many jurisdictions treat SARMs sold for human consumption as \u003cstrong data-end=\"7857\" data-start=\"7831\"\u003eunlawful or controlled\u003c\/strong\u003e. Grey-market powders\/capsules often have \u003cstrong data-end=\"7932\" data-start=\"7899\"\u003emislabeling and contamination\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7938\" data-start=\"7935\"\u003e\n\u003ch2 data-end=\"7986\" data-start=\"7940\"\u003e7. Comparative Snapshot (SARMs \u0026amp; anabolics)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"8655\" data-start=\"7988\"\u003e\n\u003cthead data-end=\"8098\" data-start=\"7988\"\u003e\n\u003ctr data-end=\"8098\" data-start=\"7988\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7998\" data-start=\"7988\"\u003eFeature\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"8019\" data-start=\"7998\"\u003e\u003cstrong data-end=\"8018\" data-start=\"8000\"\u003eS-4 (Andarine)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"8046\" data-start=\"8019\"\u003e\u003cstrong data-end=\"8045\" data-start=\"8021\"\u003eLGD-4033 (Ligandrol)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"8072\" data-start=\"8046\"\u003e\u003cstrong data-end=\"8071\" data-start=\"8048\"\u003eRAD-140 (Testolone)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"8098\" data-start=\"8072\"\u003e\u003cstrong data-end=\"8096\" data-start=\"8074\"\u003eTestosterone (TRT)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"8655\" data-start=\"8121\"\u003e\n\u003ctr data-end=\"8239\" data-start=\"8121\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8134\" data-start=\"8121\"\u003eAR profile\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8174\" data-start=\"8134\"\u003e\u003cstrong data-end=\"8173\" data-start=\"8136\"\u003ePartial agonist, tissue-selective\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8194\" data-start=\"8174\"\u003ePotent AR agonist\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8223\" data-start=\"8194\"\u003ePotent, somewhat selective\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8239\" data-start=\"8223\"\u003eFull agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8296\" data-start=\"8240\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8253\" data-start=\"8240\"\u003eBone focus\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8266\" data-start=\"8253\"\u003e\u003cstrong data-end=\"8265\" data-start=\"8255\"\u003eStrong\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8275\" data-start=\"8266\"\u003eStrong\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8286\" data-start=\"8275\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8296\" data-start=\"8286\"\u003eStrong\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8381\" data-start=\"8297\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8320\" data-start=\"8297\"\u003eProstate stimulation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8345\" data-start=\"8320\"\u003e\u003cstrong data-end=\"8344\" data-start=\"8322\"\u003eLower; sometimes ↓\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8356\" data-start=\"8345\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8367\" data-start=\"8356\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8381\" data-start=\"8367\"\u003e\u003cstrong data-end=\"8379\" data-start=\"8369\"\u003eHigher\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8469\" data-start=\"8382\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8395\" data-start=\"8382\"\u003eVision AEs\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8431\" data-start=\"8395\"\u003e\u003cstrong data-end=\"8430\" data-start=\"8397\"\u003eCharacteristic (night\/yellow)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8446\" data-start=\"8431\"\u003eNone typical\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8461\" data-start=\"8446\"\u003eNone typical\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8469\" data-start=\"8461\"\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8546\" data-start=\"8470\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8488\" data-start=\"8470\"\u003eHPT suppression\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8509\" data-start=\"8488\"\u003e\u003cstrong data-end=\"8508\" data-start=\"8490\"\u003eYes (moderate)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8524\" data-start=\"8509\"\u003eYes (strong)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8539\" data-start=\"8524\"\u003eYes (strong)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8546\" data-start=\"8539\"\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"8655\" data-start=\"8547\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8564\" data-start=\"8547\"\u003eLegal\/approval\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8591\" data-start=\"8564\"\u003e\u003cstrong data-end=\"8590\" data-start=\"8566\"\u003eUnapproved, SARM ban\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8614\" data-start=\"8591\"\u003eUnapproved, SARM ban\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8637\" data-start=\"8614\"\u003eUnapproved, SARM ban\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"8655\" data-start=\"8637\"\u003eApproved (TRT)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"8660\" data-start=\"8657\"\u003e\n\u003ch2 data-end=\"8688\" data-start=\"8662\"\u003e8. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"8993\" data-start=\"8690\"\u003e\n\u003cli data-end=\"8742\" data-start=\"8690\"\u003e\n\u003cp data-end=\"8742\" data-start=\"8692\"\u003e\u003cstrong data-end=\"8708\" data-start=\"8692\"\u003eNo approvals\u003c\/strong\u003e in US\/EU\/UK\/most jurisdictions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8875\" data-start=\"8743\"\u003e\n\u003cp data-end=\"8875\" data-start=\"8745\"\u003eUsed only in \u003cstrong data-end=\"8770\" data-start=\"8758\"\u003eresearch\u003c\/strong\u003e; any therapeutic development has \u003cstrong data-end=\"8815\" data-start=\"8804\"\u003estalled\u003c\/strong\u003e in favor of newer SARMs or different anabolic approaches.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8993\" data-start=\"8876\"\u003e\n\u003cp data-end=\"8993\" data-start=\"8878\"\u003eWidely sold online as a \u003cstrong data-end=\"8923\" data-start=\"8902\"\u003eresearch chemical\u003c\/strong\u003e, often in \u003cstrong data-end=\"8945\" data-start=\"8934\"\u003enon-GMP\u003c\/strong\u003e conditions with \u003cstrong data-end=\"8992\" data-start=\"8962\"\u003eunverified purity and dose\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8998\" data-start=\"8995\"\u003e\n\u003ch2 data-end=\"9040\" data-start=\"9000\"\u003e9. Practical Take \u0026amp; Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"9697\" data-start=\"9042\"\u003e\n\u003cli data-end=\"9157\" data-start=\"9042\"\u003e\n\u003cp data-end=\"9157\" data-start=\"9044\"\u003e\u003cstrong data-end=\"9056\" data-start=\"9044\"\u003eFor now:\u003c\/strong\u003e S-4 is best regarded as a \u003cstrong data-end=\"9130\" data-start=\"9083\"\u003ehistorical SARM prototype and research tool\u003c\/strong\u003e, not a clinical therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9342\" data-start=\"9158\"\u003e\n\u003cp data-end=\"9342\" data-start=\"9160\"\u003e\u003cstrong data-end=\"9182\" data-start=\"9160\"\u003eMain unique point:\u003c\/strong\u003e Its \u003cstrong data-end=\"9231\" data-start=\"9187\"\u003ebone-\/muscle-anabolic + prostate-sparing\u003c\/strong\u003e profile and \u003cstrong data-end=\"9276\" data-start=\"9244\"\u003edistinct visual side effects\u003c\/strong\u003e make it mechanistically interesting but clinically problematic.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9697\" data-start=\"9343\"\u003e\n\u003cp data-end=\"9371\" data-start=\"9345\"\u003e\u003cstrong data-end=\"9369\" data-start=\"9345\"\u003eResearch priorities:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"9697\" data-start=\"9374\"\u003e\n\u003cli data-end=\"9461\" data-start=\"9374\"\u003e\n\u003cp data-end=\"9461\" data-start=\"9376\"\u003eDetailed characterization of the \u003cstrong data-end=\"9429\" data-start=\"9409\"\u003eocular mechanism\u003c\/strong\u003e and long-term retinal safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9577\" data-start=\"9464\"\u003e\n\u003cp data-end=\"9577\" data-start=\"9466\"\u003eDevelopment of \u003cstrong data-end=\"9506\" data-start=\"9481\"\u003enext-generation SARMs\u003c\/strong\u003e that retain S-4’s \u003cstrong data-end=\"9552\" data-start=\"9525\"\u003ebone\/muscle selectivity\u003c\/strong\u003e without vision issues.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9697\" data-start=\"9580\"\u003e\n\u003cp data-end=\"9697\" data-start=\"9582\"\u003eMore complete mapping of \u003cstrong data-end=\"9650\" data-start=\"9607\"\u003elipid, cardiovascular, and reproductive\u003c\/strong\u003e impacts of AR partial agonism vs full agonism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684844368210,"sku":null,"price":25.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/s4_1g.png?v=1770834818","url":"https:\/\/sciencepeptideslab.com\/products\/s4andarine-1g","provider":"Science Peptides Lab","version":"1.0","type":"link"}